Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587698 | 0.91 | MEN1 (0.43) | ADRB2ALOX5NPC1LMNA | |
| SCHEMBL3585787 | 0.86 | LMNA (0.46) | ADRB2ALOX5NPC1LMNAALOX15 | |
| SCHEMBL3589737 | 0.85 | ADRB2 (0.39) | ADRB2ALOX5NPC1 | |
| SCHEMBL7118047 | 0.83 | CCR6 (0.46) | — | |
| SCHEMBL3581733 | 0.81 | MEN1 (0.45) | ADRB2ALOX5NPC1 | |
| SCHEMBL3585614 | 0.79 | ADRB2 (0.46) | ADRB2ALOX5 | |
| SCHEMBL3583408 | 0.79 | TP53 (0.43) | ALOX5TSHR | |
| SCHEMBL3578370 | 0.79 | ALDH1A1 (0.45) | LMNA | |
| SCHEMBL2546820 | 0.77 | CYP3A4 (0.54) | ALOX5NPC1LMNAMAPK1 | |
| SCHEMBL7116977 | 0.77 | KCNH2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885ALOX5 4097/4885NPC1 1697/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885ALOX5 4097/4885NPC1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.